

Pulmonary-Thoracic Oncology

December 4, 2024 at 8:00 AM – 9:00 AM

Other

Pulmonary-Thoracic Oncology Multidisciplinary Conference - 12/4/2024

Overview

Lung cancer is the most common cause of cancer deaths and has the highest case fatality rate of any cancers among men and women, and accounts for more cancer deaths annually than breast, prostate, colon and pancreatic cancer combined. This activity represent a multidisciplinary approach to the screening, diagnosis and treatment of lung cancer and associated malignancies along with a direct review of selected cases in a tumor board approach with an overall goal of reducing the impact, morbidity and mortality associated with lung cancer.

Learning Objectives

- 1 Increase screening of at risk patients
- 2 Increase detection of early stage lung cancer
- 3 Improve treatment of early stage lung cancer
- 4 Utilize the latest technologic advances in diagnosis
- 5 Optimize staging of lung cancer patients
- 6 Determine the optimal treatment of lung cancer patients
- 7 Understand the importance of shared decision making in patient management
- 8 Facilitate access to the detection, diagnosis and treatment of lung cancer in underrepresented and economically disadvantaged populations

Target Audience

Specialties – Internal Medicine, Medical Oncology, Pulmonary Disease
 Professions – Physician, Fellow/Resident, Nurse, Physician Assistant, Resident

Accreditation Statement



ACCME
ACCREDITED

The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statements

The David Geffen School of Medicine at UCLA designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

The individuals below have been identified as having a position to influence the content of this educational activity. As such, they have disclosed the absence or presence of a relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships for these individuals have been mitigated.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Guy W. Soo Hoo, MD	Faculty	Nothing to disclose - 07/23/2024
Guy Soo Hoo, MD	Activity Administrator	Nothing to disclose - 03/30/2024
Ann Schloss Arrieta, APRN, DNP	Activity Administrator	Nothing to disclose - 06/26/2024

Commercial Support

This activity has not received commercial support.

Connect with Us

Center for Continuing Medical Education (CCPD)

ccpd@mednet.ucla.edu

(310) 794-2620